MeiraGTx’s Phase II Gene Therapy For Parkinson’s Shows Efficacy, Safety

 
• By Joseph Haas
  
MeiraGTx has high hopes for its Parkinson's disease gene therapy candidate (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Neurological

More from R&D